Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids
An OTP, ASCL1, and HNF1A IHC panel enables the identification of molecular-defined pulmonary carcinoid subgroups with distinct clinical phenotypes and diverging therapeutic vulnerabilities that require further prospective evaluation.
Authors
- Axel zur Hausen (ORCID: https://orcid.org/0000-0002-4781-0372)
- Jan H. von der Thüsen (ORCID: https://orcid.org/0000-0001-9699-4860)
- D J G Leunissen
- Lisa M. Hillen (ORCID: https://orcid.org/0000-0002-8808-4952)
- Anne‐Marie C. Dingemans (ORCID: https://orcid.org/0000-0001-6105-182X)
- Lynnette Fernandez‐Cuesta (ORCID: https://orcid.org/0000-0002-0724-6703)
- M. Foll
- Laura Moonen (ORCID: https://orcid.org/0000-0003-3699-2534)
- Jules L. Derks (ORCID: https://orcid.org/0000-0002-0442-1879)
- N. Alcala
- Thierry van den Bosch (ORCID: https://orcid.org/0000-0002-7223-4565)
- A. Sexton Oates
- Niki L. Reynaert (ORCID: https://orcid.org/0000-0002-8577-8094)
- Esther C. van den Broek
- Michael A. den Bakker (ORCID: https://orcid.org/0000-0001-8996-3134)
- Ronald Damhuis (ORCID: https://orcid.org/0000-0001-7248-7047)
- L. Lap
- E.J.M. Speel
- T J J van Weert
Institutions
- Maastricht University Medical Centre (NL)
- Erasmus MC (NL)
- Maastricht University (NL)
- Maasstad Ziekenhuis (NL)
- Netherlands Comprehensive Cancer Organisation (NL)
- Erasmus MC Cancer Institute (NL)
- Centre international de recherche sur le cancer (FR)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1016/j.jtho.2024.11.018
- Citations
- 13
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.03
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- KWF Kankerbestrijding
- Universitair Medisch Centrum Groningen
- Institut National Du Cancer
- National Cancer Institute
- Cilag